text:
Browser MMORPG Games
League Of Angels
League of Angels is a free-to-play fantasy MMORPG game that introduces players to an array of exciting new features combined with the time tested quality of turn-based combat.Read more Play Now
Drakensang Online
Drakensang Online is a new MMORPG from developers BigPoint, in the hopes of attracting gamers to a new type of free to play browser game, BigPoint have equipped Drakensang Online with all of the little bits and pieces that forged the success of older dungeon crawler titles.Read more Play Now
Developed and published by MMO veterans R2 Games, Shadowbound is a free-to-play no download MMORPG that boasts high quality graphics amidst a high fantasy setting supported by carefully crafted landscapes, highly detailed character models and animations, and a seamless blend of PvE and PvP action.Read more Play Now
Battlestar Galactica
Battlestar Galactica Online is a free-to-play, browser-based MMO by BigPoint. Complete challenging missions from your commanding officers, and fly a Colonial Viper or Cylon Raider - or command ships never seen before now.Read more Play Now
Rail Nation
Featuring charming graphics and the easy access of a browser-based online game, Rail Nation is the perfect combination of transport simulation with strategy management features and mechanics.Read more Play Now
Browser MMORPG Games
Want to play MMORPG / MMO browser games without going through the hassle of downloading a client? Then look no further!
XMMORPG is the browser MMORPG / browser MMO games directory currently available and the place where you can find the newest, most popular and top rated browser mmo games that can be played without download. Empire Craft or RuneScape, Medieval Town Building or Shooters – pick your favorite, we have them all! Here you can rate these games and even share your reviews with Online MMORPG enthusiasts from all over the world. Many of the mmorpg / multiplayer RPG / browser mmo games listed on the site are free to play and very few require a premium membership. User votes influence our browser MMORPG / browser MMO games tops and review scores are calculated and added up on a daily basis. You can read highly detailed previews long before the games hit the streets and professional reviews on top mmorpg games. For each of these we have introduced a popularity meter so you can easily see what's hot and what's not. Choose your game from our browser MMORPG / browser MMO games lists and start playing in just seconds.
Featured MMORPG / MMO
- New Destiny Demo Detailed And Expansion Pass Reward Revealed November 20, 2014
- SMITE Roster Expands – Ao Kuang Returns In Style November 19, 2014
- Das Tal Special Stress Test This Saturday November 19, 2014
- Firefall Welcomes Update 1.2 November 19, 2014
- Top 10 AAA MMORPG Games 2014 2014-11-05 17:23:44


text:
New RoboDog from WowWee: Wrex The Dog
Lifestyle 13 Views
This is WowWee's newest robot. Watch the video review from RobotsRule, but Wrex the dog does some 'wacky' stuff (like pissing on the floor) and has a touch of Scooby Doo in him. Oh ya, he doesn't walk, he rolls.
Christen Costa
Grew up back East, got sick of the cold and headed West. Since I was small I have been pushing buttons - both electronic and human. With an insatiable need for tech I thought "why not start a blog focusing on technology, and use my dislikes and likes to post on gadgets."
Sponsored Content
Related Posts
Clef Du Vin Lets You Taste Wine The Way It Was Meant To Be
Fuelbox Wants To Be The Be-All And End-All Of Phone Chargers
The Platypus: A Boat That Half-Sinks
Google Glass Gets Fashionable, Offers Prescription Lenses
McFly High Tops and ZBoard Classic Hoverboard Edition Bundle
VisionTek Charge & Sync USB 3.0 Seven Port Hub Review
Homepage » Product Type » Lifestyle » New RoboDog from WowWee: Wrex The Dog

subset: commoncrawl


text:
My wife sent me a Borg Love Letter
I have to share the ingame mail I got from my wife last night. I play a Liberated Borg. Yes..I know I am very lucky :)
Oh borg, my borg,
with hard bits where jiggly bits oft reside,
When willst you gaze upon me
with your single laz'r'd eye?
When willst thy love upon me shine,
like a gentl'r phaser beam?
When willst thine lens begin to fog
with passion's heat-caus'd steam?
Oh, borg, my borg,
how soon can I caress thine gear so strong
Why must thou make me sit right here
and for thy presence long?
Soon, I pray, you will come
and show me your Borg-made rocket
and we together will learn, my love,
if it fits a human's socket.
That's awesome.
I wish my SO wouldn't care if I spent all week on an mmo.
captain... the nerdiness
That's adorable! I mean, not only is it sweet but it's really well-written and clever.
I really think playing games like this together is fun for a couple and gives them yet another common frame of reference for fun stuff like this. Mine and my hubby's playstyle is different so he's already higher level but when we do play together it's really fun.
WOW. Can your wife be myn too j/k
Thats really awsomes I wish my gf wrote borg love letters to me, she would get anything she wants...not she dosnt already lol
Very cool indeed.
Thank you for sharing it with us.
Over 9000!?
I was the Borg. Lower your shields and surrender yourself. I will add my biological distinctiveness to your own (which may require multiple nano-probe injections). I will adapt to satisfy you. Resistance is favorable.
I was really hoping for a crude, not so subtle, reference to sex using the words "assimilation" and "nano probes" but I guess this will do.
I wish I had a girlfriend. :(
|All times are GMT -7. The time now is 12:24 AM.


text:
Latest Headlines
Latest Headlines
Packaging, software issues account for 40% of medical device recalls, report finds
The Q3 2014 Stericycle Recall Index highlights the complexities of medical device recalls in a global economy. With greater technology comes greater responsibility to consumers, and recalls that span different countries and continents add to companies' challenges. Packaging and software issues accounted for 40% of recalls that the Index covered.
UPDATE: Mars Petcare expands recall for Pedigree dog food into more states
Mars Petcare has issued a voluntary recall for 22 bags of its Pedigree dog food that may contain small metal fragments and were sold at Dollar General stores in four states.
FDA allows Covidien to restart manufacturing of two recalled devices
The FDA approved Covidien's fixes to the manufacturing process of its recalled Pipeline Embolization Device and Alligator Retrieval Device for treating brain aneurysms.
Physicians weigh in on J&J power morcellator recall
Days after Johnson & Johnson pulled its devices for minimally invasive hysterectomies from the global market, physicians are shedding light on alternative surgical methods and questioning the recall's implications for women undergoing the procedure.
FDA hits ConvaTec with Class I recall for fecal management system
The FDA issued a Class I recall status, its most serious, to medical device maker ConvaTec for its fecal management system that is blamed for one death and a dozen injuries. The company began its own recall of the system, which was not cleared for marketing by the FDA, in April.
Covidien recalls potentially faulty Hydrofinity guidewire
Covidien has issued a recall of its Hydrofinity Hydrophilic Guidewire due to the potential for damage to the outer polymer jackets of the device during use. The company said it has notified the FDA of the action.
CareFusion runs into more 'deadly' trouble with infusion pump
CareFusion's Alaris pump is again the subject of a recall, earning the FDA's most serious designation over a software problem that can muddle scheduled infusions and put patients at risk.
Abbott's diabetes biz hit with its third Class I recall in a year
Add two more Abbott Laboratories diabetes products to the list of items deemed potentially deadly by the FDA. Five of the company's diabetes offerings have now been subject to the agency's most serious recall label in the past year.
Yes, U.S. med tech recalls have doubled since 2003--but so has the market
"Medical device recalls nearly doubled in a decade," proclaims The Wall Street Journal 's headline--a bit of data the FDA is expected to release Friday that seems likely to travel far on social media. Critics are already making hay, questioning the rigor of pre-market vetting at the FDA.
Word of a $16M Coloplast vaginal-mesh settlement spurs global resolution talk
Danish medical device maker Coloplast is said to have paid $16 million to settle lawsuits claiming it injured women with vaginal-mesh inserts. With settlement talk swirling around at least 5 more makers of the plagued devices, that has some watchers saying the time may be ripe for a global settlement.


text:
The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.
1. An isolated monoclonal antibody or antigen binding fragments thereof encoded by the clone deposited with the ATCC as Accession Number PTA-4829.
2. The isolated antibody or antigen binding fragments of
3. The isolated antibody or antigen binding fragments of
4. The isolated antibody or antigen binding fragments of
5. The isolated antibody or antigen binding fragments of
6. The isolated clone deposited with the ATCC as Accession Number PTA-4829.
7. A binding assay to determine presence of cancerous cells in a tissue sample selected from a human tumor comprising:
providing a tissue sample from said human tumor;
providing an isolated monoclonal antibody or antigen binding fragment thereof encoded by the clone deposited with the ATCC as Accession Number PTA-4829;
contacting said isolated monoclonal antibody or antigen binding fragment thereof with said tissue sample; and
determining binding of said isolated monoclonal antibody or antigen binding fragment thereof with said tissue sample;
whereby the presence of said cancerous cells in said tissue sample is indicated.
8. The binding assay of
9. A process of isolating or screening for cancerous cells in a tissue sample selected from a human tumor comprising:
providing a tissue sample from a said human tumor;
providing an isolated monoclonal antibody or antigen binding fragment thereof encoded by the clone deposited with the ATCC as Accession Number PTA-4829;
contacting said isolated monoclonal antibody or antigen binding fragment thereof with said tissue sample; and
determining binding of said isolated monoclonal antibody or antigen binding fragment thereof with said tissue sample;
whereby said cancerous cells are isolated by said binding and their presence in said tissue sample is confirmed.
10. The process of
[0001] This invention relates to the isolation and production of cancerous disease modifying antibodies (CDMAB) and to the use of these CDMAB in therapeutic and diagnostic processes, optionally in combination with one or more chemotherapeutic agents. The invention further relates to binding assays which utilize the CDMABs of the instant invention.
[0002] Each individual who presents with cancer is unique and has a cancer that is as different from other cancers as that person's identity. Despite this, current therapy treats all patients with the same type of cancer, at the same stage, in the same way. At least 30% of these patients will fail the first line therapy, thus leading to further rounds of treatment and the increased probability of treatment failure, metastases, and ultimately, death. A superior approach to treatment would be the customization of therapy for the particular individual. The only current therapy which lends itself to customization is surgery. Chemotherapy and radiation treatment can not be tailored to the patient, and surgery by itself, in most cases is inadequate for producing cures.
[0003] With the advent of monoclonal antibodies, the possibility of developing methods for customized therapy became more realistic since each antibody can be directed to a single epitope. Furthermore, it is possible to produce a combination of antibodies that are directed to the constellation of epitopes that uniquely define a particular individual's tumor.
[0004] Having recognized that a significant difference between cancerous and normal cells is that cancerous cells contain antigens that are specific to transformed cells, the scientific community has long held that monoclonal antibodies can be designed to specifically target transformed cells by binding specifically to these cancer antigens; thus giving rise to the belief that monoclonal antibodies can serve as �Magic Bullets� to eliminate cancer cells.
[0005] Monoclonal antibodies isolated in accordance with the teachings of the instantly disclosed invention have been shown to modify the cancerous disease process in a manner which is beneficial to the patient, for example by reducing the tumor burden, and will variously be referred to herein as cancerous disease modifying antibodies (CDMAB) or �anti-cancer� antibodies.
[0006] At the present time, the cancer patient usually has few options of treatment. The regimented approach to cancer therapy has produced improvements in global survival and morbidity rates. However, to the particular individual, these improved statistics do not necessarily correlate with an improvement in their personal situation.
[0007] Thus, if a methodology was put forth which enabled the practitioner to treat each tumor independently of other patients in the same cohort, this would permit the unique approach of tailoring therapy to just that one person. Such a course of therapy would, ideally, increase the rate of cures, and produce better outcomes, thereby satisfying a long-felt need.
[0008] Historically, the use of polyclonal antibodies has been used with limited success in the treatment of human cancers. Lymphomas and leukemias have been treated with human plasma, but there were few prolonged remission or responses. Furthermore, there was a lack of reproducibility and there was no additional benefit compared to chemotherapy. Solid tumors such as breast cancers, melanomas and renal cell carcinomas have also been treated with human blood, chimpanzee serum, human plasma and horse serum with correspondingly unpredictable and ineffective results.
[0009] There have been many clinical trials of monoclonal antibodies for solid tumors. In the 1980s there were at least four clinical trials for human breast cancer which produced only one responder from at least 47 patients using antibodies against specific antigens or based on tissue selectivity. It was not until 1998 that there was a successful clinical trial using a humanized anti-her 2 antibody in combination with Cisplatin. In this trial 37 patients were accessed for responses of which about a quarter had a partial response rate and another half had minor or stable disease progression.
[0010] The clinical trials investigating colorectal cancer involve antibodies against both glycoprotein and glycolipid targets. Antibodies such as 17-1A, which has some specificity for adenocarcinomas, had undergone Phase 2 clinical trials in over 60 patients with only one patient having a partial response. In other trials, use of 17-1A produced only one complete response and two minor responses among 52 patients in protocols using additional cyclophosphamide. Other trials involving 17-1A yielded results that were similar. The use of a humanized murine monoclonal antibody initially approved for imaging also did not produce tumor regression. To date there has not been an antibody that has been effective for colorectal cancer. Likewise there have been equally poor results for lung cancer, brain cancers, ovarian cancers, pancreatic cancer, prostate cancer, and stomach cancer. There has been some limited success in the use of anti-GD3 monoclonal antibody for melanoma. Thus, it can be seen that despite successful small animal studies that are a prerequisite for human clinical trials, the antibodies that have been tested have been for the most part ineffective.
[0011] Prior Patents:
[0012] U.S. Pat. No. 5,750,102 discloses a process wherein cells from a patient's tumor are transfected with MHC genes which may be cloned from cells or tissue from the patient. These transfected cells are then used to vaccinate the patient.
[0013] U.S. Pat. No. 4,861,581 discloses a process comprising the steps of obtaining monoclonal antibodies that are specific to an internal cellular component of neoplastic and normal cells of the mammal but not to external components, labeling the monoclonal antibody, contacting the labeled antibody with tissue of a mammal that has received therapy to kill neoplastic cells, and determining the effectiveness of therapy by measuring the binding of the labeled antibody to the internal cellular component of the degenerating neoplastic cells. In preparing antibodies directed to human intracellular antigens, the patentee recognizes that malignant cells represent a convenient source of such antigens.
[0014] U.S. Pat. No. 5,171,665 provides a novel antibody and method for its production. Specifically, the patent teaches formation of a monoclonal antibody which has the property of binding strongly to a protein antigen associated with human tumors, e.g. those of the colon and lung, while binding to normal cells to a much lesser degree.
[0015] U.S. Pat. No. 5,484,596 provides a method of cancer therapy comprising surgically removing tumor tissue from a human cancer patient, treating the tumor tissue to obtain tumor cells, irradiating the tumor cells to be viable but non-tumorigenic, and using these cells to prepare a vaccine for the patient capable of inhibiting recurrence of the primary tumor while simultaneously inhibiting metastases. The patent teaches the development of monoclonal antibodies which are reactive with surface antigens of tumor cells. As set forth at col. 4, lines 45 et seq., the patentees utilize autochthonous tumor cells in the development of monoclonal antibodies expressing active specific immunotherapy in human neoplasia.
[0016] U.S. Pat. No. 5,693,763 teaches a glycoprotein antigen characteristic of human carcinomas and not dependent upon the epithelial tissue of origin.
[0017] U.S. Pat. No. 5,783,186 is drawn to Anti-Her2 antibodies which induce apoptosis in Her2 expressing cells, hybridoma cell lines producing the antibodies, methods of treating cancer using the antibodies and pharmaceutical compositions including said antibodies.
[0018] U.S. Pat. No. 5,849,876 describes new hybridoma cell lines for the production of monoclonal antibodies to mucin antigens purified from tumor and non-tumor tissue sources.
[0019] U.S. Pat. No. 5,869,268 is drawn to a method for generating a human lymphocyte producing an antibody specific to a desired antigen, a method for producing a monoclonal antibody, as well as monoclonal antibodies produced by the method. The patent is particularly drawn to the production of an anti-HD human monoclonal antibody useful for the diagnosis and treatment of cancers.
[0020] U.S. Pat. No. 5,869,045 relates to antibodies, antibody fragments, antibody conjugates and single chain immunotoxins reactive with human carcinoma cells. The mechanism by which these antibodies function is two-fold, in that the molecules are reactive with cell membrane antigens present on the surface of human carcinomas, and further in that the antibodies have the ability to internalize within the carcinoma cells, subsequent to binding, making them especially useful for forming antibody-drug and antibody-toxin conjugates. In their unmodified form the antibodies also manifest cytotoxic properties at specific concentrations.
[0021] U.S. Pat. No. 5,780,033 discloses the use of autoantibodies for tumor therapy and prophylaxis. However, this antibody is an antinuclear autoantibody from an aged mammal. In this case, the autoantibody is said to be one type of natural antibody found in the immune system. Because the autoantibody comes from �an aged mammal�, there is no requirement that the autoantibody actually comes from the patient being treated. In addition the patent discloses natural and monoclonal antinuclear autoantibody from an aged mammal, and a hybridoma cell line producing a monoclonal antinuclear autoantibody.
[0022] The instant inventors have previously been awarded U.S. Pat. No. 6,180,357, entitled �Individualized Patient Specific Anti-Cancer Antibodies� directed to a process for selecting individually customized anti-cancer antibodies which are useful in treating a cancerous disease.
[0023] This application utilizes the method for producing patient specific anti-cancer antibodies as taught in the '357 patent for isolating hybridoma cell lines which encode for cancerous disease modifying monoclonal antibodies. These antibodies can be made specifically for one tumor and thus make possible the customization of cancer therapy. Within the context of this application, anti-cancer antibodies having either cell-killing (cytotoxic) or cell-growth inhibiting (cytostatic) properties will hereafter be referred to as cytotoxic. These antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat tumor metastases.
[0024] The prospect of individualized anti-cancer treatment will bring about a change in the way a patient is managed. A likely clinical scenario is that a tumor sample is obtained at the time of presentation, and banked. From this sample, the tumor can be typed from a panel of pre-existing cancerous disease modifying antibodies. The patient will be conventionally staged but the available antibodies can be of use in further staging the patient. The patient can be treated immediately with the existing antibodies, and a panel of antibodies specific to the tumor can be produced either using the methods outlined herein or through the use of phage display libraries in conjunction with the screening methods herein disclosed. All the antibodies generated will be added to the library of anti-cancer antibodies since there is a possibility that other tumors can bear some of the same epitopes as the one that is being treated. The antibodies produced according to this method may be useful to treat cancerous disease in any number of patients who have cancers that bind to these antibodies.
[0025] In addition to anti-cancer antibodies, the patient can elect to receive the currently recommended therapies as part of a multi-modal regimen of treatment. The fact that the antibodies isolated via the present methodology are relatively non-toxic to non-cancerous cells allows for combinations of antibodies at high doses to be used, either alone, or in conjunction with conventional therapy. The high therapeutic index will also permit re-treatment on a short time scale that should decrease the likelihood of emergence of treatment resistant cells.
[0026] Furthermore, it is within the purview of this invention to conjugate standard chemotherapeutic modalities, e.g. radionuclides, with the CDMABs of the instant invention, thereby focusing the use of said chemotherapeutics.
[0027] If the patient is refractory to the initial course of therapy or metastases develop, the process of generating specific antibodies to the tumor can be repeated for re-treatment. Furthermore, the anti-cancer antibodies can be conjugated to red blood cells obtained from that patient and re-infused for treatment of metastases. There have been few effective treatments for metastatic cancer and metastases usually portend a poor outcome resulting in death. However, metastatic cancers are usually well vascularized and the delivery of anti-cancer antibodies by red blood cells can have the effect of concentrating the antibodies at the site of the tumor. Even prior to metastases, most cancer cells are dependent on the host's blood supply for their survival and anti-cancer antibody conjugated to red blood cells can be effective against in situ tumors as well. Alternatively, the antibodies may be conjugated to other hematogenous cells, e.g. lymphocytes, macrophages, monocytes, natural killer cells, etc.
[0028] There are five classes of antibodies and each is associated with a function that is conferred by its heavy chain. It is generally thought that cancer cell killing by naked antibodies are mediated either through antibody dependent cellular cytotoxicity or complement dependent cytotoxicity. For example murine IgM and IgG2a antibodies can activate human complement by binding the C-1 component of the complement system thereby activating the classical pathway of complement activation which can lead to tumor lysis. For human antibodies the most effective complement activating antibodies are generally IgM and IgG1. Murine antibodies of the IgG2a and IgG3 isotype are effective at recruiting cytotoxic cells that have Fc receptors which will lead to cell killing by monocytes, macrophages, granulocytes and certain lymphocytes. Human antibodies of both the IgG1 and IgG3 isotype mediate ADCC.
[0029] Another possible mechanism of antibody mediated cancer killing may be through the use of antibodies that function to catalyze the hydrolysis of various chemical bonds in the cell membrane and its associated glycoproteins or glycolipids, so-called catalytic antibodies.
[0030] There are two additional mechanisms of antibody mediated cancer cell killing which are more widely accepted. The first is the use of antibodies as a vaccine to induce the body to produce an immune response against the putative cancer antigen that resides on the tumor cell. The second is the use of antibodies to target growth receptors and interfere with their function or to down regulate that receptor so that effectively its function is lost.
[0031] Accordingly, it is an objective of the invention to utilize a method for producing cancerous disease modifying antibodies from cells derived from a particular individual which are cytotoxic with respect to cancer cells while simultaneously being relatively non-toxic to non-cancerous cells, in order to isolate hybridoma cell lines and the corresponding isolated monoclonal antibodies and antigen binding fragments thereof for which said hybridoma cell lines are encoded.
[0032] It is an additional objective of the invention to teach cancerous disease modifying antibodies and antigen binding fragments thereof.
[0033] It is a further objective of the instant invention to produce cancerous disease modifying antibodies whose cytotoxicity is mediated through antibody dependent cellular toxicity.
[0034] It is yet an additional objective of the instant invention to produce cancerous disease modifying antibodies whose cytotoxicity is mediated through complement dependent cellular toxicity.
[0035] It is still a further objective of the instant invention to produce cancerous disease modifying antibodies whose cytotoxicity is a function of their ability to catalyze hydrolysis of cellular chemical bonds.
[0036] A still further objective of the instant invention is to produce cancerous disease modifying antibodies which are useful for in a binding assay for diagnosis, prognosis, and monitoring of cancer.
[0037] Other objects and advantages of this invention will become apparent from the following description wherein are set forth, by way of illustration and example, certain embodiments of this invention.
[0038]FIG. 1 includes representative FACS histograms of 10A327.6 antibodies, isotype control antibodies, anti-EGFR antibodies directed against several cancer cell lines and non-cancer cells.
[0039] It is to be understood that while a certain form of the invention is illustrated, it is not to be limited to the specific form or arrangement herein described and shown. It will be apparent to those skilled in the art that various changes may be made without departing from the scope of the invention and the invention is not to be considered limited to what is shown and described in the specification.
[0040] One of the potential benefits of monoclonal antibodies with respect to the treatment of cancer is their ability to specifically recognize single antigens. It was thought that in some instances cancer cells possess antigens that were specific to that kind of transformed cell. It is now more frequently believed that cancer cells have few unique antigens, rather, they tend to over-express a normal antigen or express fetal antigens. Nevertheless, the use of monoclonal antibodies provided a method of delivering reproducible doses of antibodies to the patient with the expectation of better response rates than with polyclonal antibodies.
[0041] Traditionally, monoclonal antibodies have been made according to fundamental principles laid down by Kohler and Milstein. Mice are immunized with antigens, with or without adjuvants. The splenocytes are harvested from the spleen for fusion with immortalized hybridoma partners. These are seeded into microtitre plates where they can secrete antibodies into the supernatant that is used for cell culture. To select from the hybridomas that have been plated for the ones that produce antibodies of interest the hybridoma supernatants are usually tested for antibody binding to antigens in an ELISA (enzyme linked immunosorbent assay) assay. The idea is that the wells that contain the hybridoma of interest will contain antibodies that will bind most avidly to the test antigen, usually the immunizing antigen. These wells are then subcloned in limiting dilution fashion to produce monoclonal hybridomas. The selection for the clones of interest is repeated using an ELISA assay to test for antibody binding. Therefore, the principle that has been propagated is that in the production of monoclonal antibodies the hybridomas that produce the most avidly binding antibodies are the ones that are selected from among all the hybridomas that were initially produced. That is to say, the preferred antibody is the one with highest affinity for the antigen of interest.
[0042] There have been many modifications of this procedure such as using whole cells for immunization. In this method, instead of using purified antigens, entire cells are used for immunization. Another modification is the use of cellular ELISA for screening. In this method instead of using purified antigens as the target in the ELISA, fixed cells are used. In addition to ELISA tests, complement mediated cytotoxicity assays have also been used in the screening process. However, antibody-binding assays were used in conjunction with cytotoxicity tests. Thus, despite many modifications, the process of producing monoclonal antibodies relies on antibody binding to the test antigen as an endpoint.
[0043] Most antibodies directed against cancer cells have been produced using the traditional methods outlined above. These antibodies have been used both therapeutically and diagnostically. In general, for both these applications, the antibody has been used as the targeting agent that delivers a payload to the site of the cancer. These antibody conjugates can either be radioactive, toxic, or serve as an intermediary for further delivery of a drug to the body, such as an enzyme or biotin. Furthermore, it was widely held, until recently, that naked antibodies had little effect in vivo. Both HERCEPTIN and RITUXIMAB are humanized murine monoclonal antibodies that have recently been approved for human use by the FDA. However, both these antibodies were initially made by assaying for antibody binding and their direct cytotoxicity was not the primary goal during the production of hybridomas. Any tendency for these antibodies to produce tumor cell killing is thus through chance, not by design.
[0044] Although the production of monoclonal antibodies have been carried out using whole cell immunization for various applications, the screening of these hybridomas have relied on either putative or identified target antigens or on the selectivity of these hybridomas for specific tissues. It is axiomatic that the best antibodies are the ones with the highest binding constants. This concept originated from the basic biochemical principle that enzymes with the highest binding constants were the ones that were the most effective for catalyzing a reaction. This concept is applicable to receptor ligand binding where the drug molecule binding to the receptor with the greatest affinity usually has the highest probability for initiating or inhibiting a signal. However, this may not always be the case since it is possible that in certain situations there may be cases where the initiation or inhibition of a signal may be mediated through non-receptor binding. The information conveyed by a conformational change induced by ligand binding can have many consequences such as a signal transduction and endocytosis, among others. The ability to produce a conformational change in a receptor molecule may not necessarily be due to the filling of a ligand receptor pocket but may occur through the binding of another extracellular domain or due to receptor clustering induced by a multivalent ligand.
[0045] The production of antibodies to produce cell killing need not be predicated upon screening of the hybridomas for the best binding antibodies. Rather, although not advocated by those who produce monoclonal antibodies, the screening of the hybridoma supernatants for cell killing or alternatively for cessation of growth of the cancerous cells may be selected as a desirable endpoint for the production of cytotoxic or cytostatic antibodies. It is well understood that in-vivo antibodies mediate their function through the Fc portions and that part of the utility of the therapeutic antibody is determined by the functionality of the constant region or attached moieties. In this case the FAb portion of the antibody, the antigen-combining portion, commonly referred to as the antigen binding fragment, will confer to the antibody its specificity and the Fc portion its functionality. The antigen combining site of the antibody can be considered to be the product of a natural combinatorial library. The result of the rearrangement of the variable region of the antibody can be considered a molecular combinatorial library where the output is a peptide. Therefore, the sampling of this combinatorial library can be based on any parameter. Like sampling a natural compound library for antibiotics, it is possible to sample an antibody library for cytotoxic or cytostatic compounds.
[0046] The various endpoints in a screen must be differentiated from each other. For example, the difference between antibody binding to the cell is distinct from cell killing. Cell killing (cytotoxicity) is distinct from the mechanisms of cell death such as oncosis or apoptosis. There can be many processes by which cell death is achieved and some of these can lead either to oncosis or apoptosis. There is speculation that there are other cell death mechanisms other than oncosis or apoptosis but regardless of how the cell arrives at death there are some commonalities of cell death. One of these is the absence of metabolism and another is the denaturation of enzymes. In either case vital stains will fail to stain these cells. These endpoints of cell death have been long understood and predate the current understanding of the mechanisms of cell death. Furthermore, there is the distinction between cytotoxic effects where cells are killed and cytostatic effects where the proliferation of cells are inhibited.
[0047] In a preferred embodiment of the present invention, the assay is conducted by focusing on cytotoxic activity toward cancerous cells as an end point. In a preferred embodiment, a live/dead assay kit, for example the LIVE/DEAD� Viability/Cytotoxicity Assay Kit (L-3224) by Molecular Probes, is utilized. The Molecular Probes kit provides a two-color fluorescence cell viability assay that is based on the simultaneous determination of live and dead cells with two probes that measure two recognized parameters of cell viability�intracellular esterase activity and plasma membrane integrity. The assay principles are general and applicable to most eukaryotic cell types, including adherent cells and certain tissues, but not to bacteria or yeast. This fluorescence-based method of assessing cell viability is preferred in place of such assays as trypan blue exclusion, Cr release and similar methods for determining cell viability and cytotoxicity.
[0048] In carrying out the assay, live cells are distinguished by the presence of ubiquitous intracellular esterase activity, determined by the enzymatic conversion of the virtually nonfluorescent cell-permeant CALCEIN AM to the intensely fluorescent Calcein. The polyanionic dye Calcein is well retained within live cells, producing an intense uniform green fluorescence in live cells (ex/em �495 nm/�515 nm). EthD-1 enters cells with damaged membranes and undergoes a 40-fold enhancement of fluorescence upon binding to nucleic acids, thereby producing a bright red fluorescence in dead cells (ex/em �495 nm/�635 nm). EthD-1 is excluded by the intact plasma membrane of live cells. The determination of cell viability depends on these physical and biochemical properties of cells. Cytotoxic events that do not affect these cell properties may not be accurately assessed using this method. Background fluorescence levels are inherently low with this assay technique because the dyes are virtually nonfluorescent before interacting with cells.
[0049] In addition to the various endpoints for screening, there are two other major characteristics of the screening process. The library of antibody gene products is not a random library but is the product of a biasing procedure. In the examples below, the biasing is produced by immunizing mice with cells. This increases the proportion of antibodies that have the potential to bind the target antigen. Although immunization is thought of as a way to produce higher affinity antibodies (affinity maturation) in this case it is not. Rather, it can be considered as a way to shift the set of antigen combining sites towards the targets. This is also distinct from the concept of isotype switching where the functionality, as dictated by the constant portion of the heavy chain, is altered from the initial IgM isotype to another isotype such as IgG.
[0050] The third key feature that is crucial in the screening process is the use of multitarget screening. To a certain extent specificity is related to affinity. An example of this is the situation where an antigen has very limited tissue distribution and the affinity of the antibody is a key determinant of the specificity of the antibody-the higher the affinity the more tissue specific the antibody and likewise an antibody with low affinity may bind to tissues other than the one of interest. Therefore, to address the specificity issue the antibodies are screened simultaneously against a variety of cells. In the examples below the hybridoma supernatants (representing the earliest stages of monoclonal antibody development), are tested against a number of cell lines to establish specificity as well as activity.
[0051] The antibodies are designed for therapeutic treatment of cancer in patients. Ideally the antibodies can be naked antibodies. They can also be conjugated to a cytotoxic moiety, such as any of the well-known chemotherapeutic agents, or alternatively radioactive isotopes or toxins. They can be used to target other molecules to the cancer. e.g. biotin conjugated enzymes. When radioactive compounds are used for conjugation, enhanced imaging capability is achieved as well.
[0052] The antibodies can be fragmented and rearranged molecularly. For example Fv fragments can be made; sFv-single chain Fv fragments; diabodies etc.
[0053] It is envisioned that these cancerous disease modifying antibodies or antigen binding fragments thereof can be used for diagnosis, prognosis, and monitoring of cancer. For example the patients can have blood samples drawn for shed tumor antigens which can be detected by these antibodies in different formats such as ELISA assays, rapid test panel formats etc. The antibodies can be used to stain tumor biopsies for the purposes of diagnosis. In addition a panel of therapeutic antibodies can be used to test patient samples to determine if there are any suitable antibodies for therapeutic use.
[0054] The hybridoma cell line 10A327.6 was deposited, in accordance with the Budapest Treaty, with the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209 on Nov. 26, 2002, under Accession Number PTA-4829. In accordance with 37 CFR 1.808, the depositors assure that all restrictions imposed on the availability to the public of the deposited materials will be irrevocably removed upon the granting of a patent.
[0055] To produce the hybridoma that produces anti-cancer antibody single cell suspensions of human colon cancer cells were prepared in cold PBS. IMMUNEASY� (Qiagen, Venlo, Netherlands) adjuvant was prepared for use by gentle vortexing. 100 microliters of IMMUNEASY� mouse adjuvant were added to 10 million colon cancer cells in the microcentrifuge tube and mixed and left at room temperature for 15 min. Eight to nine week old BALB/c mice were immunized by injecting 100 microliters of the antigen-adjuvant containing 2.5 million cells intramuscularly. Freshly prepared antigen-adjuvant was used to boost the immunized mice two weeks after the initial immunization at 2.5 million cells in 250 microliters by an intraperitoneal injection. A spleen was used for fusion two days after the last immunization. The hybnidomas were prepared by fusing the isolated splenocytes with NSO-1 myeloma partners. The supernatants from the fusions were tested for subcloning of the hybridomas.
[0056] To determine whether the antibodies secreted by hybridoma cells are of the IgG or IgM isotype, an ELISA assay was employed. 100 microliters/well of goat anti-mouse IgG+IgM (H+L) at a concentration of 2.4 micrograms/mL in coating buffer (0.1M carbonate/bicarbonate buffer, pH 9.2-9.6) at 4� C. was added to the ELISA plates overnight. The plates were washed thrice in washing buffer (PBS+0.05% Tween). 100 microliters/well blocking buffer (5% milk in wash buffer) was added to the plate for 1 hr. at room temperature and then washed thrice in washing buffer. 100 microliters/well of hybridoma supernatant was added and the plate incubated for 1 hr. at room temperature. The plates were washed thrice with washing buffer and 1/5000 dilution of either goat anti-mouse IgG or IgM horseradish peroxidase conjugate (diluted in PBS containing 1% bovine serum albumin), 100 microliters/well, was added. After incubating the plate for 1 hr. at room temperature the plate was washed thrice with washing buffer. 100 microliters/well of TMB solution was incubated for 1-3 minutes at room temperature. The color reaction was terminated by adding 100 microliters/well 2M H2SO4 and the plate was read at 450 nm with a Perkin-Elmer HTS7000 plate reader. As indicated in Table 1 the 10A327.6 hybridomas secreted primarily antibodies of the IgG isotype After one round of limiting dilution, hybridoma supernatants were tested for antibodies that bound to target cells in a cell ELISA assay. Three colon cancer cell lines were tested: HT-29, SW1116 and SW620. The plated cells were fixed prior to use. The plates were washed thrice with PBS containing MgCl2 and CaCl2 at room temperature. 100 microliters of 2% paraformaldehyde diluted in PBS was added to each well for ten minutes at room temperature and then discarded. The plates were again washed with PBS containing MgCl2 and CaCl2 three times at room temperature. Blocking was done with 100 microliters/well of 5% milk in wash buffer (PBS+0.05% Tween) for 1 hr at room temperature. The plates were washed thrice with wash buffer and the hybridoma supernatant was added at 100 microliters/well for 1 hr at room temperature. The plates were washed three times with wash buffer and 100 microliters/well of 1/5000 dilution of goat anti-mouse IgG or IgM antibody conjugated to horseradish peroxidase (diluted in PBS containing 1% bovine serum albumin) was added. After a one hour incubation at room temperature the plates were washed three times with wash buffer and 100 microliter/well of TMB substrate was incubated for 1-3 minutes at room temperature. The reaction was terminated with 100 microliters/well 2M H2SO4 and the plate read at 450 nm with a Perkin-Elmer HTS7000 plate reader. The results as tabulated in Table 1 were expressed as the number of folds above background compared to the IgG isotype control (3BD-27). The antibodies from the 10A327.6 hybridoma had 7.2 fold greater binding above control in the HT-29 cell line, and 23.7 fold greater binding in the SW1116 cell line. This indicated that the antibody bound differentially to an antigen that was expressed more so on some cancer cells than others.
[0057] In conjunction with testing for antibody binding the cytotoxic effect of the hybridoma supernatants were tested in the same colon cancer cell lines: HT-29, SW1116 and SW620. The Live/Dead cytotoxicity assay was obtained from Molecular Probes (Eu, Oreg.). The assays were performed according to the manufacturer's instructions with the changes outlined below. Cells were plated before the assay at the predetermined appropriate density. After 2 days, 100 microliters of supernatant from the hybridoma microtitre plates were transferred to the cell plates and incubated in a 5% CO2 incubator for 5 days. The wells that served as the positive controls were aspirated until empty and 100 microliters of sodium azide and/or cycloheximide was added. 3BD-27 monoclonal antibody was also added as an isotype control since it was known not to bind to HT-29 colon cancer cells. An anti-EGFR antibody (C225) was also used in the assay for comparison. After 5 days of treatment, the plate was then emptied by inverting and blotted dry. Room temperature DPBS containing MgCl2 and CaCl2 was dispensed into each well from a multichannel squeeze bottle, tapped three times, emptied by inversion, and then blotted dry. 50 microliters of the fluorescent Live/Dead dye diluted in DPBS containing MgCl2 and CaCl2 was added to each well and incubated at 37� C. in a 5% CO2 incubator for 30 minutes. The plates were read in a Perkin-Elmer HTS7000 fluorescence plate reader and the data was analyzed in Microsoft Excel. The results were tabulated in Table 1. The 10A327.6 hybridoma antibodies in the supernatant produced 16% cytotoxicity in HT-29 cells and 28% cytotoxicity in SW1116 cells. This indicated the antibody derived from the hybridoma cell can produce cytotoxicity in cancer cells. As shown in Table 1 there was a tendency to produce cytotoxicity when the antibody bound the cell being tested. This was seen in the example of 16% HT-29 cytotoxicity associated with a 7.2 fold increase in binding over the background. In another example there was a 28% cytoxicity in SW1116 colon cancer associated with a 23.7 fold increase in binding over the background. In this example when there was no significant binding of the antibody to SW620 colon cancer cells there was no significant cytotoxicity. As tabulated in Table 1 the 3BD-27 antibody, of the same isotype as the 10A327.6 antibody and previously known not to bind to HT-29 colon cancer cells, did not produce cytotoxicity in that cancer cell line. The known non-specific cytotoxic agents sodium azide and cycloheximide produced cytotoxicity as expected. By way of comparison the well defined anti-cancer antibody C225 produced 13% cytotoxicity in SW1116 cancer cells. As shown in Table I the antibodies from the hybridoma 10A327.6 produced cytotoxicity against cancers from different individuals, bound to those cancer cells, and had properties of specificity in that the antibodies produced no cytotoxicity when that antibody did not bind to those cells.
[0058] Antibody Production
[0059]10A327.6 monoclonal antibody was produced by culturing the hybridomas in CL-1000 flasks (BD Biosciences, Oakville, ON) with collections and reseeding occurring twice/week and standard antibody purification procedures with Protein G Sepharose 4 Fast Flow (Amersham Biosciences, Baie d'Urf�, QC). It is within the scope of this invention to utilize monoclonal antibodies which are humanized, chimerized or murine antibodies. 10A327.6 was compared to a number of both positive (anti-Fas (EOS9.1, IgM, kappa, 20 mg/mL, eBioscience, San Diego, Calif.), anti-Her2/neu (IgG1, kappa, 10 mg/mL, Inter Medico, Markham, ON), anti-EGFR (C225, IgGI, kappa, 5 mg/mL, Cedarlane, Hornby, ON), Cycloheximide (100 mM, Sigma, Oakville, ON), NaN3 (0.1%, Sigma, Oakville, ON)) and negative (107.3 (anti-TNP, IgG1, kappa, 20 mg/mL, BD Biosciences, Oakville, ON), G155-178 (anti-TNP, IgG2a, kappa, 20 mg/mL, BD Biosciences, Oakville, ON), MPC-11 (antigenic specificity unknown, IgG2b, kappa, 20 mg/mL), J606 (anti-fructosan, IgG3, kappa, 20 mg/mL), IgG Buffer (2%)) controls in a cytotoxicity assay (Table 2).
[0060] Breast cancer (MB-231, MB-468, MCF-7), colon cancer (HT-29, SW1116, SW620), lung cancer (NCI H460), ovarian cancer (OVCAR), prostate cancer (PC-3), and non-cancer (CCD 27sk, Hs888 Lu) cell lines were tested (all from the ATCC, Manassas, Va.). The Live/Dead cytotoxicity assay was obtained from Molecular Probes (Eugene, Oreg.). The assays were performed according to the manufacturer's instructions with the changes outlined below. Cells were plated before the assay at the predetermined appropriate density. After 2 days, 100 microliters of purified antibody was diluted into media, and then were transferred to the cell plates and incubated in a 5% CO2 incubator for 5 days. The plate was then emptied by inverting and blotted dry. Room temperature DPBS containing MgCl2 and CaCl2 was dispensed into each well from a multichannel squeeze bottle, tapped three times, emptied by inversion and then blotted dry. 50 microliters of the fluorescent Live/Dead dye diluted in DPBS containing MgCl2 and CaCl2 was added to each well and incubated at 37� C. in a 5% CO2 incubator for 30 minutes. The plates were read in a Perkin-Elmer HTS7000 fluorescence plate reader and the data was analyzed in Microsoft Excel and the results were tabulated in Table 2.
[0061] The data represented an average of four experiments tested in triplicate and presented qualitatively in the following fashion: 4/4 experiments greater than threshold cytotoxicity (+++), 3/4 experiments greater than threshold cytotoxicity (++), 2/4 experiments greater than threshold cytotoxicity (+). Unmarked cells in Table 2 represented inconsistent or effects less than the threshold cytotoxicity. The 10A327.6 produced 90% cytotoxicity in an ovarian cancer cell line compared to C225, a well studied anti-cancer antibody, demonstrating properties of specific cytotoxicity towards cancer cells.
[0062] Importantly the isolated antibody did not produce cytotoxicity against a number of non-cancer cells such as CCD 27sk or Hs888 Lu. The chemical cytotoxic agents induced their expected cytotoxicity while a number of other antibodies which were included for comparison also performed as expected given the limitations of biological cell assays. It was observed the MCF-7 breast cancer cell line had cytotoxicity in response to two negative control antibodies and the results from the anti-Fas, anti-Her2/neu, and anti-EGFR antibodies may be due to an increased susceptibility to antibodies in general. However, it was also observed 10A327.6 antibodies did not produce cytotoxicity in MCF-7 cancer cells, another possible indication of specificity due to combination of antibody activity and antigen expression.
[0063] Cells were prepared for FACS by initially washing the cell monolayer with DPBS (without Ca++ and Mg++). Cell dissociation buffer (INVITROGEN) was then used to dislodge the cells from their cell culture plates at 37� C. After centrifugation and collection the cells were resuspended in Dulbecco's phosphate buffered saline containing MgCl2 and CaCl2, containing 25% fetal bovine serum at 4� C. (wash media) and counted, aliquoted to appropriate cell density, spun down to pellet the cells and resuspended in staining media (DPBS containing MgCl2, CaCl2 and 2% fetal bovine serum) at 4� C. in the presence of test antibodies (10A327.6) or control antibodies (isotype control or anti-EGF-R) at 20 micrograms/mL on ice for 30 minutes. Prior to the addition of Alexa Fluor 488-conjugated secondary antibody the cells were washed once with wash media. The Alexa Fluor 488-conjugated antibody in staining media was then added for 20 minutes. The cells were then washed for the final time and resuspended in staining media containing 1 microgram/mL propidium iodide. Flow cytometric acquisition of the cells was assessed by running samples on a FACScan using the CellQuest software (BD Biosciences). The forward (FSC) and side scatter (SSC) of the cells were set by adjusting the voltage and amplitude gains on the FSC and SSC detectors. The detectors for the three fluorescence channels (FL1, FL2, and FL3) were adjusted by running cells stained with purified isotype control antibody followed by Alexa Fluor 488-conjugated secondary antibody such that cells had a uniform peak with a median fluorescent intensity of approximately 1-5 units. Live cells were acquired by gating for FSC and propidium iodide exclusion. For each sample, approximately 10,000 live cells were acquired for analysis and the results presented in Table 3.
[0064] Table 3 tabulated the mean fluorescence intensity fold increase above isotype control and is presented qualitatively as: less than 5 (−); 5 to 50 (+); 50 to 100 (++); above 100 (+++) and in parenthesis, the percentage of cells stained.
[0065] Representative histograms of 10A327.6 antibodies were compiled for FIG. 1 and evidence the binding characteristics of the 10A327.6 antibody, inclusive, in some instances, of bimodal peaks.
[0066] 10A327.6 displayed binding to both breast cancers (MDA-MB-231) and colon cancers (HT-29, SW1116) and no binding to the normal skin line, CCD-27sk, an indication of the specificity of the antibody. The shift in fluorescence intensity between the two types of colon cancer cells is an indication that 10A327.6 antibody binds differentially to the colon cancer cells.
[0067] All patents and publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains. All patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.
[0068] It is to be understood that while a certain form of the invention is illustrated, it is not to be limited to the specific form or arrangement of parts herein described and shown. It will be apparent to those skilled in the art that various changes may be made without departing from the scope of the invention and the invention is not to be considered limited to what is shown and described in the specification. One skilled in the art will readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. Any oligonucleotides, peptides, polypeptides, biologically related compounds, methods, procedures and techniques described herein are presently representative of the preferred embodiments, are intended to be exemplary and are not intended as limitations on the scope. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention and are defined by the scope of the appended claims. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in the art are intended to be within the scope of the following claims.
Referenced by
Legal Events
Original Image


text:
Home » Posts tagged"Brendan Gleeson"
14 Feb 2013
Trailer for Redford/LaBeouf starrer The Company You Keep »
The film teams the veteran filmmaker and heartthrob with young Shia LaBeouf, and is a political thriller about a former 1970s Weather Underground militant (Redford) who must go on the run when outed by a young reporter (LaBeouf)
25 May 2012
Albert Nobbs »
A touching narrative that seeps into the modern subconscious
The Cup »
the somewhat dated execution will limit its appeal
Safe House »
A live action re-enactment of Peter Griffin battling the Giant Chicken on "Family Guy"!
2 Jan 2012
New Poster for Denzel Washington's Safe House »
No one is safe.
4 Nov 2011
Trailer for Denzel Washington, Ryan Reynolds thriller Safe House »
Tanit Phoenix also in flick
11 Oct 2011
Twilight and Iron Man stars board Robert Redford's next »
"The Company You Keep" adds five more


text:
Keep your frequent searches in one place.
Keep your favourite homes in one place.
Main content:
2 beds, 2 baths, 1 parking
Available for rent on a minimum 6 month lease.
2 Bedroom - 2 Bathroom fully furnished apartment in NIrvana By The Sea at Kirra.
Contact James Nikiforides , RAAS Real Estate - Brisbane
2 beds, 2 baths, 2 parking
This luxury apartment faces directly north commanding extensive Ocean views, is of superior quality and is arguably the best 2 bedroom l...
Contact Lloyd Collingwood , RAAS Real Estate - Brisbane
4 beds, 2 baths, 1 parking
Four bedroom house sized duplex in central Coolangatta. Modern interiors throughout with large open plan kitchen and living opening ont...
Roslyn Foley
McGrath Coolangatta/Tweed Head…
This well presented unit offers you
* 2 good size bedrooms with built in wardrobes
* 2 bathrooms with the main bedroom being ensuite...
Brooke Mason
Century 21 On The Border
Well presented, first level two bedroom apartment just an easy 250mts stroll to Kirra's famous beaches, cafe's & restaurants.
Ray White Tweed Heads
2 beds, 1 bath, 1 parking
Beautiful renovation with new kitchen to impress the discerning.
Enjoy Two bedrooms with the perfect northerly aspect.
An absolutely s...
Located just behind Goodwin Park in Coolangatta, sits this two bedroom unit elevated on the top floor to capture those summer breezes.
2 beds, 1 bath
Freshly painted with new flooring and vanity is this cozy neat & tidy 2 bedroom unit.
Ground floor with street parking & communal lau...
Angela Molloy
Rainbow Bay Realty
2 beds, 1 bath, 1 parking
This newly renovated unit is only minutes to the beach and the local cafes of Kirra. The unit offers floating timber flo...
Add Inspection: Tue 25 Nov 3.00PM
2 beds, 2 baths, 1 parking
Situated on the 6th floor of Sanbano Coolangatta, enjoy stunning ocean views from your new luxury 2 bedroom fully furnis...
Situated on the 7th floor of Sanbano Coolangatta, enjoy ocean views from your new luxury 2 bedroom fully furnished apart...
So central, no car required, moments from the Gold Coast's best beaches, stroll to cafes & restaurants.
2 bedroom 2 levels 1 full bat...
Lynne Wallace
Ray White Mermaid Beach
Ground floor fully refurbished two bedroom unit situated in a central location within minutes to the local shops & beaches. This unit un...
Leasing Department
Ray White Coolangatta/Tweed He…
1 bed, 1 bath
If you love the beach then, then you will love this location. This is a one bedroom lowset unit which is centrally loca...
Login to ignore properties you don't like. If you're not a Fairfax Media member,
sign up for free.
Properties will display with a grey shadow to make it easier to skip past and you won't receive home alert updates for these properties.
Enter your Domain, or Fairfax Media account login and password
Unsure of your account login?
Your account login will be one of two things. It will either be your email address,
or it will be the username you entered when you first registered (e.g. JohnD).
Still not sure of your account login?
Click here to have your account details emailed to you.
Forgot password?
More pages:
e.g. suburb, keywords, bedrooms, features, etc
Select a criteria to refine by:
Currently selected:
Not included
Currently selected:
Currently selected: Any
*POI data Copyright. Based on data provided under license from POIDB.com, TerraPages Pty Ltd & PSMA Australia Limited. Disclaimer.


text:
Photo shootout: Nokia Lumia 1020, PureView 808, Lumia 925, HTC One, and iPhone 5
Summary: It's pretty clear that the Nokia Lumia 1020 has the most advanced camera software in a smartphone today and as you can see in this image gallery of shots around Seattle they have the proof to back up their claim as camera phone champion.
TOPICS: Mobility, Nokia, Reviews, Smartphones, AT&T, Windows Phone
49 of 74Image
Sony Xperia Z
Lumia 1020 with WP default app
Lumia 1020 reframed example
Kick off your day with ZDNet's daily email newsletter. It's the freshest tech news and opinion, served hot. Get it.


text: Strict Standards: Redefining already defined constructor for class XML_Parser in /home/sites/www.americanpoems.com/web/store/aom/includes/os.php on line 1188 Strict Standards: Declaration of XML_Parser::raiseError() should be compatible with PEAR::raiseError($message = NULL, $code = NULL, $mode = NULL, $options = NULL, $userinfo = NULL, $error_class = NULL, $skipmsg = false) in /home/sites/www.americanpoems.com/web/store/aom/includes/os.php on line 1604 Strict Standards: Declaration of XML_Unserializer::startHandler() should be compatible with XML_Parser::startHandler($xp, $elem, &$attribs) in /home/sites/www.americanpoems.com/web/store/aom/includes/os.php on line 3503 Strict Standards: Declaration of Cache_Lite_File::get() should be compatible with Cache_Lite::get($id, $group = 'default', $doNotTestCacheValidity = false) in /home/sites/www.americanpoems.com/web/store/aom/includes/cache.php on line 1020 American Poems: Books: Avogadro Corp: The Singularity Is Closer Than It Appears (Singularity Series Book 1) Home Apparel Appliances Books DVD Electronics Home & Garden Kindle eBooks Magazines Music Outdoor Living Software Tools & Hardware PC & Video Games Search All Products Apparel Appliances Arts & Crafts Automotive Baby Beauty Books Computers DVD Electronics Gourmet Food Grocery Health Home & Garden Industrial & Science Jewelry Kindle eBooks Kitchen Magazines Miscellaneous Mobile Apps MP3 Downloads Music Musical Instruments Office Products Outdoor Living Pet Supplies Photo & Camera Shoes Software Sporting Goods Tools & Hardware Toys VHS Video On Demand PC & Video Games Watches Wireless Wireless Accessories Advanced Search Sitemap View Cart Checkout Location: Home » Books » Avogadro Corp: The Singularity Is Closer Than It Appears (Singularity Series Book 1) Avogadro Corp: The Singularity Is Closer Than It Appears (Singularity Series Book 1) enlarge Author:William Hertling Publisher:Liquididea Press Category:eBooks In Stock Sales Rank:24,551 Format:Kindle eBook Language:English (Published) Media:Kindle Edition Edition:2 Pages:300 Publication Date:January 9, 2014 ASIN:B006ACIMQQ Also Available In: Audible Audio Edition - Avogadro Corp: The Singularity Is Closer Than It Appears Paperback - Avogadro Corp: The Singularity Is Closer Than It Appears Similar Items: A.I. Apocalypse (Singularity Series Book 2) The Last Firewall (Singularity Series Book 3) Influx Kill Decision Freedom (TM) (Daemon Book 2) Editorial Reviews: SynopsisDavid Ryan is the designer of ELOPe, an email language optimization program, that if successful, will make his career. But when the project is suddenly in danger of being canceled, David embeds a hidden directive in the software accidentally creating a runaway artificial intelligence. David and his team are initially thrilled when the project is allocated extra servers and programmers. But excitement turns to fear as the team realizes that they are being manipulated by an A.I. who is redirecting corporate funds, reassigning personnel and arming itself in pursuit of its own agenda. WINNER SCIENCE FICTION DIY BOOK FESTIVAL 2011-2012 FOREWORD REVIEWS SCIENCE FICTION BOOK OF THE YEAR 2011 "Avogadro Corp is a tremendous book that every single person needs to read. In the vein of Daniel Suarez's Daemon and Freedom(TM), William's book shows that science fiction is becoming science fact. Avogadro Corp describes issues, in solid technical detail, that we are dealing with today that will impact us by 2015, if not sooner. Not enough people have read these books. It's a problem for them, but not for the [emergent] machines." -- Brad Feld, managing directory Foundry Group, co-founder Techstars "Highly entertaining, gripping, thought inspiring book. Don't start without the time to finish — it won't let you go." -- Gifford Pinchot III, founder Bainbridge Graduate Institute, author THE INTELLIGENT ORGANIZATION "An alarming and jaw-dropping tale about how something as innocuous as email can subvert an entire organization. I found myself reading with a sense of awe, and read it way too late into the night." -- Gene Kim, author of VISIBLE OPS "A fictional world where Portland is the hub for the most exciting advancements in technology... [J]am packed with great references to deep Portland culture...and Portlandia-type references" -- SILICON FLORIST "Hertling builds a picture of how an AI could emerge, piece by piece, from technology available today. A fascinating, logical, and utterly believable scenario - I just hope nobody tries this at home." -- Nathaniel Rutman, Senior Systems Architect CERTAIN CONTENT THAT APPEARS ON THIS SITE COMES FROM AMAZON SERVICES LLC. THIS CONTENT IS PROVIDED 'AS IS' AND IS SUBJECT TO CHANGE OR REMOVAL AT ANY TIME. Brought to you by American Poems Categories •Apparel •Appliances •Arts & Crafts •Automotive •Baby •Beauty •Books •Computers •DVD •Electronics •Gourmet Food •Grocery •Health •Home & Garden •Industrial & Science •Jewelry •Kindle eBooks •Kitchen •Magazines •Miscellaneous •Mobile Apps •MP3 Downloads •Music •Musical Instruments •Office Products •Outdoor Living •Pet Supplies •Photo & Camera •Shoes •Software •Sporting Goods •Tools & Hardware •Toys •VHS •Video On Demand •PC & Video Games •Watches •Wireless •Wireless Accessories Subcategories Literature & Fiction •Action & Adventure •African American •Ancient & Medieval Literature •British & Irish •Classics •Contemporary •Dramas & Plays •Erotica •Essays & Correspondence •Foreign Language Fiction •Genre Fiction •Historical Fiction •History & Criticism •Humor & Satire •Literary •Mythology & Folk Tales •Poetry •Short Stories & Anthologies •United States •Women's Fiction •World Literature Related Categories •Literature & Fiction Subjects Books •Technothrillers Thrillers & Suspense Mystery, Thriller & Suspense Subjects Books •High Tech Science Fiction Science Fiction & Fantasy Subjects Books •Technothrillers Thrillers Mystery, Thriller & Suspense Kindle eBooks Categories •Hard Science Fiction Science Fiction Science Fiction & Fantasy Kindle eBooks Categories


text:
The pop singer's trainer, Kit Rich, shares Ke$ha's best moves. Try 'em and you just may want to leave the pants at home, too.
more slideshows
Home for the Holidays: The Essential Packing ListHoliday travel has a way of bringing its own mini-vortex
Gluten-Free Thanksgiving Stuffing RecipesThe Thanksgiving table just wouldn't be the same without turkey,
You'll be Thankful For These Cozy-Chic Holiday EnsemblesTo Grandmother's House We Go
How to Get Ke$ha's Sexy Legs
KEYWORDS: Kesha,Legs,Lower Body,Sculpt,Workouts
Hide comments Show comments
Loading Comments...


text:
Articles related to fishing definitions
All About Fishing Tackle - Fishing Tackle - Saltwater Fishing
Apr 8, 2007 ... Here are a number of articles with tips, suggestions, definitions and just plain old "how to" information about fishing tackle. These can help you ...
Glossary, a definition of fishing terms - Freshwater Fishing - About.com
Glossary. Brush up on your fishing vocabulary here in the Glossary section, where we explain the terms that are used in the sport.
Head Boat Fishing - Saltwater Fishing - About.com
In this piece we are looking at another method available to the boatless, albeit a little more expensive. I'm talking about charter boat fishing, and more ...
Fish - Animals and Wildlife - About.com
The term fish is used to refer to any aquatic vertebrate that has a skin covered with scales, two sets of paired fins, some unpaired fins, and a set of gills. Fish do ...
Traditional Economy (Definition, Examples, and Details)
Oct 13, 2014 ... A traditional economy relies on hunting, fishing and agriculture and is ... Definition, Examples, Characteristics, Advantages and Disadvantages.
What Is Overfishing? - Marine Life - About.com
Overfishing can lead to depletion of or extinction of fish populations. ... Definition: Overfishing is, simply put, when so many fish are caught that the population ...
Forest Resource Glossary and Definition of Terms - F - Forestry
Forest Resource Glossary and Definition of Terms: cold water fisheries warm water fish water fishery forestry terms fish harvest.
What Is a Hook? - Songwriting Definition
"You can't catch a fish when your fishing rod is missing a hook. ... In this context you can say songwriting is somewhat like fishing; make your hook strong and ...
What Is a Pescatarian? A Definition - Vegetarian Food - About.com
Definition: Occasionally used to describe those who abstain from eating all meat and animal flesh with the exception of fish. Although the word is not commonly ...
Fish Poker Term -- Defintion of the Poker Term Fish - About.com
What are "Fish" in poker? ... refer to our privacy policy for contact information. Definition: A bad or weak poker player. A sucker. Also Known As: donkey, pigeon ...


text:
Showing posts for 'Customize'. Clear search
Need help designing your Zenfolio website? Warren Creative Design can help
July 10, 2012 - An Expert Look at Customization, a new Blog post from Shari Warren with creative ideas and new ways to approach design i...Read the Full Post »
Creating a Custom Theme
July 26, 2010 - A professional-looking Web site is an essential part of representing your brand, telling your unique story, showcasing y...Read the Full Post »
Recent PostsFriday Foto Favorites 11.28 Product Spotlight: Video in Photoshop Friday Foto Favorites 11.21 Behind the Shot Friday Foto Favorites 11.14 Photographer's Corner: The Art of Fine Art Photography Save 30% on High-Quality Prints Friday Foto Favorites 11.7 Day in the Life of a Zenfolio Engineer Q&A with the 2014 Pink Lady® Food Photographer of the Year
January February March April May June July August September October November December


text:
Loading ...
British Traditions manufactures authentic European country furniture, relying on modern production techniques and more than 20 finishes to create antique replicas for dining rooms, bedrooms, and living areas. High-quality, new home furnishings are created with a strong emphasis on design and meticulous craftsmanship, such as dovetail drawers and mortise-and-tenon construction. Customers can flaunt their studiousness with the richly appointed Castletown desk with shelf ($1,530+) or show off fine china and silly straws with a classic hutch ($1,230+). The Marleybone entertainment center ($1,605+) swathes the customer's plasma television in style, and the 60-inch English farmhouse table ($1,080+) allows levitating plates a brief moment of respite. British Traditions' 20 unique finishes, ranging from hand-applied English wax to distressed alternatives, allows patrons to customize individual pieces to their personal taste and décor.
At eight showrooms across the Kansas City area, SleepOne Mattress Superstore's aptly named sleep advisors recommend mattresses that will accommodate budgets and physical conditions such as stiffness and pain. After scouring the showroom's floor, the staff might suggest a Sterns and Foster mattress made with materials such as silk and cashmere. They also offer delivery and removal of the old mattresses.
SleepOne Mattress Superstore also fights nightmares with several guarantees. For example, their staff will refund 110% of the difference in price if customers find the same mattress sold for less. They also exchange mattresses for up to a year (only charging a redelivery fee) and offer a rehabilitation program for reformed boogeymen.
ImPulse Fitness' passionate instructors center their classes on camaraderie and supportive energy. Bootycamp fitness classes combine resistance and cardio training to sculpt muscles into toned masterpieces. A veteran Zumba instructor leads international-rhythm-inspired workouts, getting participants to sweat in the original universal language of dance aerobics. The turbo-kick class combines aerobic exercise with muscle-building martial-arts moves, and Vinyasa flow and Hatha yoga classes home in on body, mind, and spirit. Students can also develop abdominal prowess and articulate bellybuttons during shimmy-inducing belly-dance classes.
The space-making mavens of Life Uncluttered assess customers' storage needs and create custom closet systems that can hold 50%–70% more than their disorganized predecessors. In an initial meeting, clients communicate their storage needs to an experienced designer, who will then translate these ethereal organization fantasies into a three-dimensional computer model of a new custom closet or five-dimensional model of a new alien hangout. Revamped closet spaces will have dedicated wardrobe real estate for sweaters, long dresses, and suits, and allow parents to stop using children's bedrooms as catchalls for novelty tennis shoe collections. Though costs vary based on the size of each customer's closet, a basic white closet organization system runs approximately $70 per linear foot, with the average closet costing $2,000–$2,500 depending on the addition of drawers ($300+/drawer section) and additional color choices.
Ranchview Floral has been in business since 1947, assembling flower arrangements that add a touch of beauty to decades of celebrations and expressions of sympathy. The Ranchview team expertly combines roses, tulips, daisies, and orchids into creations bursting with color, from bouquets to centerpieces and corsages. Each one makes a classic and fragrant gift for special occasions or a fancy meal for a pet goat.
Rensen House of Lights has been Kansas City's leading supplier of all your home lighting and ceiling fan needs. But we are much more than just lighting. Home decor accessories, accent furniture pieces, framed art and mirrors, are just part of the "Total Look".


text:
Sherre, I am sorry but I am in the middle of moving my family tree to a different address. As soon as I have it up and running again I will let you know and will probably post it on the Sprigg Family Genealogy Forum as well.
I do not have any of the names you have mentioned in my files. Do you have any others?
Let me know.
Scott Tappen in Michigan
Notify Administrator about this message?
|Home | Help | About Us | Site Index | Jobs | PRIVACY | Affiliate
|© 2007 The Generations Network


text:
Find a location
Or Search By
Find a Consultant
Start typing the first name or last name of the consultant you are looking for
Can't find who you're looking for? Try searching for a consultant by location or service
Find a condition
Can't find what you're looking for?
View the full list
Dr David Kingsley, Consultant Child and Adolescent Psychiatrist and Medical Director at Priory Hospital Cheadle Royal explains how parents and carers can help children and young people keep themselves emotionally healthy...
When you think about men's health what goes through your mind? Do you go straight to physical health issues like obesity and testicular cancer? Does mental health ever cross your mind?
Within the past five years there has been a 65% rise in the number of older women treated for alcoholism, according to figures from Public Health England.
Do you often work longer in the night? Do you spend a lot of time partying with friends into the early hours? Or do you have younger children who often keep you awake at night?
Says the letter from the wife of a service user cared for by Priory
Oliver House School in Chorley, part of Priory Education Services, has received Autism Accreditation from the National Autism Society (NAS).
Legal highs and synthetic drugs have become more and more common, especially on the club scene and with young adults. The various new styles of drugs attempt to mimic the effects of illicit drugs such as cocaine, heroin and cannabis.
The Priory Hospital Glasgow's Medical Director, Dr Alex Yellowlees, will be speaking at a Self Harm and Eating Disorders conference in Glasgow this week.
The Priory Group has appointed Dr Felix Davies as Director of Community Mental Health.
Addiction can affect anyone, whatever their race, gender or socio-economic status and it's estimated that there are around 1.6 million people dependent on alcohol alone here in the UK.
Welcome to the latest from the Priory news section; this section is constantly updated with the latest news and blogs from the firm.
Five simple ways to improve the emotional health of young people you care about
Men's Health: "We are stronger when we accept and address our weaknesses"
Lonely and dependent: why are more older women turning to alcohol?
No sleep tonight – how poor sleep affects your mental health
2014 November
2014 October
2014 September
2014 August
2014 July
2014 June
2014 May
2014 April
2014 March
2014 February
2014 January
2013 December
2013 November
2013 October
2013 September
2013 August
2013 July
2013 June
2013 May
2013 April
2013 March
2013 February
2013 January
2012 December
2012 November
2012 October
2012 September
2012 August
2012 July
2012 June
2012 May
2012 April
2012 March
2012 February
2012 January
2011 December
2011 November
2011 September
2011 August
2011 July
2011 June
2011 May
2011 March
2011 January
0845 277 4679
0845 277 4679
Email us
The Priory Group aspires to deliver the highest quality of care across our range of services, which include acute and complex mental healthcare, addiction treatment and low and medium secure facilities.
Read more
We use cookies so that you can view all the features and functionality of our website. If you continue browsing we'll assume that you agree to accept Cookies from the Priory Group website. You can change your cookie settings here at a later date if you change your mind.


text:
Eddie Money
Presented by One World Theatre at One World Theatre
January 18, 2013
ddie Money first made a mark in the Rock and Roll world with his 1977 eponymous debut album, buoyed by the success of two of his most famous hits, "Baby Hold On" and "Two Tickets to Paradise". Along with having sold more than 28 million records, Money followed the success of his first album with a stream of Top 40 hits, as well as some of the era's most creative videos for songs like "Think I'm in Love" and "Shakin." In 1986, Money released Can't Hold Back, which featured the chart-topping, Grammy-Nominated duet with Ronnie Spector, "Take Me Home Tonight" and the hit "I Wanna Go Back." His popularity has carried over to film, TV and video games, with his tunes appearing in dozens of movies, television shows, and hit video games like "Grand Theft Auto" and "Guitar Hero."
7701 Bee Caves Road
Austin, TX 78746
Admission Info:
$30 - $70
General Day and Time Info:
7:00 & 9:30pm
Phone: (512) 32.WORLD
Accessibility Information:
Facebook Comments
Member Reviews
There are currently no reviews/comments for this event. Be the first to add a review/comment , and let folks know what you think!
View Events by Area
Featured Sections
- Classified Ads
Check out our classfieds or submit one of your own
- Reviews
Read reviews and submit your own
- Promote Your Own Event
Submit a listing today
- Follow Our Blog on Wordpress
Get the inside scoop
- Follow us on Twitter
Discover what's happening right now
- Classified Ads
Support The Austin Creative Alliance
NowPlayingAustin.com is a service of the Austin Creative Alliance, a nonprofit organization providing critical support services for Austin's creative community across all sectors and disciplines.


text:
On November 22, 2011, Rikers Island guards put Kevin Phillip into a segregation housing unit. It was punishment for something he did. Phillip spent 36 days there. On two Fridays over that stretch, Phillip asked the guards if he could attend a Muslim prayer service at the jail. The guards said that h ... More >>
Hip-hop's first prominent Latino DJ offers a grisly but triumphant memoir
A Queens rap icon scrambles to prepare for life on the inside


text:
Temple Owls
Minnesota, Temple included in next year's Puerto Rico Tipoff field
Nov 21, 2014, 9:52 AM EST
Both Miami (2007) and Minnesota (2010) have won the event in the past.
2014-15 Season Preview: Does SMU have what it takes to win the American?
Nov 6, 2014, 11:15 AM EST
The American is wide open with the departure of Louisville.
Temple transfer guard to make season debut December 18
Nov 5, 2014, 7:14 PM EST
The NCAA offered Jesse Morgan two options: play the first 19 games, or the final 21 (and postseason). And he took the option most people would take Wednesday.
Three-star forward/center becomes Temple's third commitment in 2015 class
Oct 12, 2014, 6:27 PM EST
After going through a rough 2013-14 season, Temple's recent run of recruiting success is an important development for the program.
Temple lands their second top 150 recruit in the 2015 class
Sep 30, 2014, 8:48 AM EST
The Owls may not have landed Jalen Brunson, but they did bring in an elite "legacy" in the back court.
Assigned Reading: "The Owl Without a Vowel"
Sep 23, 2014, 4:54 PM EST
Bill Mlkvy is one of the greatest players in the history of Temple Basketball.
Three-star center has four official visits set
Sep 20, 2014, 10:15 AM EST
A three-star forward has four schools that are heavily involved.
Four-star 2015 shooting guard sets announcement date
Sep 10, 2014, 11:04 PM EST
The Philadelphia-area product is down to six schools and has taken official visits to two of them.
American Athletic Conference releases 2014-15 schedule
Aug 29, 2014, 10:49 AM EST
The teams expected by many to finish in the top five will all face each other twice in 2014-15.
Former Temple great returns to join Fran Dunphy's coaching staff
Aug 21, 2014, 4:37 PM EST
Aaron McKie ranks sixth on Temple's all-time scoring list, and he played 13 seasons in the NBA.
Five-star point guard Jalen Brunson sets all five official visits
Aug 9, 2014, 1:05 PM EST
The point guard is a top-15 recruit in the Class of 2015.
Temple's first 2015 verbal commitment is an important one for head coach Fran Dunphy
Aug 7, 2014, 8:23 PM EST
Trey Lowe was one of the best scorers in New Jersey last season, averaging nearly 28 points per game at Ewing High School.
Rick Brunson used Patrick Ewing's name to deceive masseuse which led to his arrest
Jul 8, 2014, 10:19 PM EST
Rick Brunson was arrested on June 25.
Coaches vs. Cancer Classic matchups announced
Jun 25, 2014, 5:57 PM EST
The championship rounds will be played on November 21 & 22 at the Barclays Center in Brooklyn.
Report: Temple to hire Jalen Brunson's father
Jun 25, 2014, 1:41 PM EST
Rick is the father of a very good recruit. Interesting, isn't it?
American Athletic Conference Catchup: More membership changes on the way
May 13, 2014, 4:00 PM EST
The American boasts the reigning national champion, but another team may be the early favorite to win the league in 2014-15.
Five-star 2015 point guard Jalen Brunson announces eight finalists
May 3, 2014, 5:20 PM EST
Point guard Jalen Brunson, one of the best players in the 2015 class, announced his final eight schools on Saturday via his Twitter account.
Temple forward Daniel Dingle receives medical redshirt
Mar 28, 2014, 10:51 AM EST
Temple sophomore forward Daniel Dingle, who played in ten games before suffering a torn meniscus, received some good news as his medical hardship waiver request was approved.
Report: Anthony Lee to transfer out of Temple
Mar 18, 2014, 9:55 AM EST
Expect a number of high-profile programs to show interest in the 6-foot-8 forward.
Late Night Snacks: Georgetown likely NIT bound following loss to DePaul
Mar 13, 2014, 1:46 AM EST
Most of the teams on the bubble managed to take care of business, with Georgetown being the lone exception. And American became the latest team to earn a spot in the NCAA tournament field.
No. 23 SMU's loss at Temple damages a resume that lacks quality road wins
Feb 16, 2014, 4:33 PM EST
With home wins over UConn, Memphis and Cincinnati, No. 23 SMU has three quality wins that look good on their NCAA tournament resume. Based largely upon those results, Larry Brown's Mustangs look to be well-positioned to make their first NCAA tournament appearance since 1993. However, results like Sunday's 71-64 loss at Temple won't do SMU…
Late Night Snacks: Arizona State, Harvard earn double overtime victories
Feb 15, 2014, 12:32 AM EST
GAME OF THE NIGHT: Arizona State 69, No. 2 Arizona 66 (2OT) A Jermaine Marshall layup with 14 seconds remaining in double over time gave Arizona State a lead it would not relinquish, with the Sun Devils adding a quality win to its NCAA tournament resume. Marshall finished the game with 29 points and Jahii Carson…
No. 15 Cincinnati survives at Temple, but did they lose Justin Jackson?
Jan 26, 2014, 6:34 PM EST
Sean Kilpatrick scored 29 points to lead the way for No. 15 Cincinnati in a win over Temple on Sunday afternoon, but moving to 8-0 in AAC play was a much tougher task than the Bearcats expected. Playing without Justin Jackson for much of the game after the senior center injured his ankle, Cincinnati still…
No. 24 Memphis overpowers depleted Temple for road AAC win
Jan 11, 2014, 5:30 PM EST
Memphis capped a strong week in the American Athletic Conference with its 79-69 win over Temple on Saturday to give the Tigers their second road win in AAC play this week. The No. 24 Tigers (12-3, 3-1) were in a bad place last Saturday, when Cincinnati thoroughly outplayed Memphis in the FedEx Forum, but Memphis…
Temple guard Will Cummings latest Owl to suffer an injury
Jan 10, 2014, 9:52 AM EST
To say that Temple's first season in the American Athletic Conference has been a tough one would be an understatement. Fran Dunphy's team began the season with ten players, making it even more important for the Owls to avoid the injury bug. Unfortunately for Temple that hasn't been the case, with multiple players having already…
Top Posts
- Wisconsin wins 2014 Battle 4 Atlantis with 69-56 win over Oklahoma 0
- Right wrist injury to sideline Maryland senior wing four weeks 0
- Bronson Koenig, Duje Dukan step forward in No. 2 Wisconsin's win over Georgetown 0
- St. John's seniors say they 'grew up' against Minnesota, but have they? 1
- The little things made a big difference in No. 3 Arizona's win over No. 15 San Diego State 1
- Butler upsets No. 5 North Carolina in Battle 4 Atlantis opener 2
- If No. 12 Villanova doesn't have a star on their roster, no one told JayVaughn Pinkston 0
Most Commented
- Villanova's win is evidence of why VCU may have peaked as a basketball program (14)
- Rick Pitino on blow out win: 'We played four white guys and an Egyptian' (14)
- Michigan's John Beilein rips ESPN for late tip time during Tuesday's loss (13)
- Penn State unveils new uniforms for next two games (6)
- College Basketball Talk's latest top 25: Kentucky reigns, but how far will Kansas, Florida slide? (5)


text:
Kurt's Blog
Kurt's Blog
Friday, June 21, 201306/21/2013
Kurt's Blog: North, New Britney, & Most Disappointing Album Ever?
What was the most disappointing album you've ever bought?
Thursday, June 20, 201306/20/2013
Kurt's Blog: Sleepless in Urbandale, Miley, Kanye, and Making It Count!
Miley Cyrus continues to baffle me…Kanye continues to annoy me…and should we be adding fruit to our cookies?
Wednesday, June 19, 201306/19/2013
Kurt's Blog: A Trip to the Henry Doorly Zoo
What? A good-natured, family-oriented blog post? I promise to not let that happen again!
Monday, June 17, 201306/17/2013
Kurt's Blog: Ken & Coll Got Me Hooked, and Now I'm an Addict
I haven't watched it now in just about 12 hours…and I need a fix!
Friday, June 14, 201306/14/2013
Kurt's Blog: Ranking Superman & Happy Father's Day!
8-year old Kurt would despise what I'm about to write about Superman!
Thursday, June 13, 201306/13/2013
Kurt's Blog: Getting Only 3 Hours Of Sleep Was Well Worth It
I'll sacrifice sleep for triple overtime victories anyday…everyday!
Wednesday, June 12, 201306/12/2013
Kurt's Blog: Summer Finally Arrived? Head to the Beach!
Going to the beach sounds great…but my kids just wanted a sandbox apparently.
Tuesday, June 11, 201306/11/2013
Kurt's Blog: Sabbath, Goo, & Lonely Islands
Goo, Sabbath, and a Lonely Island…a Trifecta of Lists!
Friday, June 7, 201306/07/2013
Kurt's Blog: Am I Really Prepared for Duck Fatherhood?
Plus a very fun music video from a local musician!
Thursday, June 6, 201306/06/2013
Kurt's Blog: Save Floppy!
Plus, the correct way to eat Oreos!


text:
We use cookies on our site to make sure we give you the best service possible. To give your consent, carry on shopping, or find out more about cookies here.
To save your basket we require your email address
Please enter your email address below to save your basket
By submitting your details, you are agreeing to receive information about ao.com products and services via email. ao.com will not share your details with any other organisation. For further details please see our online Privacy Policy.
recommend us
Log in for a personalised experience
People on facebook are saying
Please enter your email address
Please enter your email address below to save this product
Short or long wash – you choose. With the Time Manager setting on the EWX127410W, you can increase or decrease the length of each wash to suit your timetable. There's a 7kg drum to fill so you'll get 35 shirts in no problem – it turns into 12 shirts when you're drying because clothes need more room to breathe. Don't worry about checking them to see if their ready, sensors inside the drum automatically do this and stop the cycle once everything's dry.
Give our sales team a call on0844 324 9222 and we'll happily price match
Famously Flexible
1 of 1 (100%) reviewers would recommend this product to a friend
Pros: Easy to use, Good build quality, Quiet, looks good
"I bought this machine to replace an earlier version, some 14 years old. Very happy with the old machine so I wanted to replace 'like with like' as far as possible. The new machine has a digital readout which shows time remaining before the wash is finished - very useful. Lots of other small but significant improvements too. Much quieter than the machine it replaces! It's basically an AEG machine without the AEG badge as far as I can tell. Recommended."
6 of 6 people found this review helpful.
Was this review helpful to you?
4 / 5
5 / 5
Reviewed by: Jamesthephoto
Location: Grantham, UK
Gender: Male
Age: Over 65
Family size: Couple
Want to write a review? Click here
"I bought this machine to replace an earlier version, some 14 years old. Very happy with the old machine so I wanted to replace 'like with like' as far as possible. The new machine has a digital readou..."
There's every programme you can think of on the EWX127410W. As well as all the traditional washes like Cottons, Synthetics and Delicates, there are some specialist options for your wool, silk and even items that are labelled Hand Wash Only. So there's no need to spend an afternoon soaking your expensive clothes in the bathtub, just pop them in the machine and you can have it washed, dried and ready to wear in no time.
There's a really handy Easy Iron cycle too – it soaks clothes, rather than scrubs them, so they don't end up full of creases. Just choose the Iron Dry option and the EWX127410W leaves a little moisture in the fabric, making your ironing much easier.
For sensitive skin, and those with allergies, there's an Extra Rinse option. This gives your clothes one more rinse to make sure every single trace of dirt, pet hair and detergent is gone.
If you like to get your washing and drying done while you're out at work, or maybe overnight (if you've got cheaper electricity rates then) there's a Delay Start to make use of. This lets you put your cycle on hold for up to 20 hours, so it doesn't matter when you load the machine, you can time it to finish whenever you want.
We know a new appliance is an investment, whether your old one has broken down or you're kitting out a new home. That's why we offer the option to Pay on Finance. If you spend £249 or more online, you can choose to spread the cost of your purchase over a time to suit you, whether it's 6, 12, 24, 36 or 48 months. Just select the Pay on Finance option when you check out.
We want our Pay on Finance option to be as easy to understand and straightforward as possible. We've created the chart below to tell you how much you'll pay back per month.
If your application is successful, you'll be asked to verify your identity by authorising a 50p transaction against a credit or debit card that you own. This helps protect you and us against fraudulent finance contracts. No money will be taken from your card, the details are only used to check that they are valid and registered to your address.
Pay on Finance for interest-bearing credit products is available over 12, 24, 36 or 48 months, subject to status. From time to time, we may offer an interest-free credit product over 6 or 12 month terms, at our discretion. To be eligible to apply for finance, you must be 18 or older, in regular employment and have been a UK resident for more than 3 years. Other conditions may apply and we cannot guarantee that your application will be accepted. Stock will not be allocated until the application has been completed and approved. We reserve the right to withdraw finance on certain products at any time. Pay on Finance is provided through our external partner, V12. If your application is successful you'll enter into a credit agreement with Secure Trust Bank Plc; V12's parent company.
Should you cancel your credit agreement and have already received products from us, then you will be liable to pay us in full for the product (unless your cancellation rights apply).
Finance is available on orders of £249 or more, placed on our website. This amount includes any additional services and delivery options selected, however does not take into account any promotions, such as cashback.
You'll need to be:
Other conditions may apply and we cannot guarantee that your application will be accepted.
* If you are retired and receive a pension, V12 Retail Finance may ask for proof of sufficient income.
You should get an instant answer on whether your application for finance has been successful. In some cases, V12 – our 3rd party financial services provider - will need to look at the application in more detail before making their decision.
All you need to do is fill out the online form at the payment stage and add an electronic signature. It's important you use your full name and address details and make sure everything is spelt correctly. Please note, this is an online only finance option.
If your application is successful, you'll be asked to verify your identity by authorising a 50p transaction against a credit or debit card that you own. This helps protect you and us against fraudulent finance contracts. No money will be taken from your card; the details are only used to check that they are valid and registered to your address.
Applications may not be accepted for a number of reasons, including mis-typed information, or not meeting the specified requirements. Please note that other conditions may apply and we cannot guarantee that your application will be accepted.
If your application isn't successful, you can still purchase the item in full via PayPal or with a valid credit or debit card. If your application is declined, it's usually for one of the following reasons:
If you wish to appeal the decision made by V12, it's advised you obtain an up to date copy of your credit report before appealing directly to V12. Due to data protection, all customer appeals must be email to firstname.lastname@example.com or for more advice, call V12 on 02920 468916.
We've teamed up with V12 Retail Finance Limited ("V12") to offer you a flexible and affordable option to pay on finance. V12 is the UK's only specialist provider of Retail Point of Sale Credit, providing finance options for more than 20 years through its industry leading online paperless processing system. If your application is successful, you will enter into a Credit Agreement with Secure Trust Bank Plc (V12's parent company) which will be administered by V12. V12 is authorised and regulated by the Financial Conduct Authority. Secure Trust Bank Plc is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority under registration number 204550.
2 mins 22 seconds
19 seconds
18 seconds
23 seconds
22 seconds
21 seconds
26 seconds
24 seconds
29 seconds
30 seconds
38 seconds
27 seconds
20 seconds
view more
ao.com is operated by AO Retail Limited.
The goods you buy from this site will be purchased from AO Retail Limited
Proud to be part of AO Retail Limited | company number 3914998
Thanks very much.
Welcome to ao.com! To ensure emails arrive in your inbox please add email@example.com to your safe folder, address book or approved email addresses.
AO Newsletter
Great deals Brilliant giveaways
Item added to your basket


text:
Thank you for taking the time to seek us out. We are a small, vibrant community in the heart of a thriving village just off junction 12 of the M1. If you decide to visit us, you will receive a warm welcome as we seek to encounter and demonstrate the love of God both in our Sunday services (10.30am) and out and about in the community week by week. If you have any questions or would like to comment on what you discover at TBC, then don't hesitate to contact me.
Every blessing in Christ.
Pastor Scott Carr
The Year of the Lord's FavourSpeaker: Scott CarrTags: God's friend, Good News, Isaiah 61, Servant of the Lord
God IS goodSpeaker: Steve le PageTags: Goddness of God, Romans 11, the love of God.
Truth v CounterfeitSpeaker: Scott CarrTags: guidance, http://toddingtonbaptist.co.uk/wp-content/uploads/2014/11/Truth-v-Counterfeit26-10-2014.mp3, spiritual gifts, supernatural, the New Age, Truth
Testimony of SurrenderSpeaker: Colin KayeTags: feeding the hungry, miracles, provision, testimonies
Unconditional LoveSpeaker: Scott CarrTags: Love of the Father